Lynda Chin, M.D., Ph.D.

Scientific Director, M.D. Anderson Cancer Center
The University of Texas

Dr. Lynda Chin graduated with an M.D. degree from Albert Einstein College of Medicine in 1993 and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she completed in parallel her residency training in the hospital and postdoctoral fellowship in the laboratory.  For the 13 years prior to joining the University of Texas MD Anderson Cancer Center in 2011, Dr. Chin was a professor of dermatology at Dana-Farber Cancer Institute and Harvard Medical School and a senior associate member of the Broad Institute of MIT and Harvard. She was also the Scientific Director of the Belfer Institute for Applied Cancer Science.   Dr. Chin is currently the founding chair of the Department of Genomic Medicine at MD Anderson. She also serves as the scientific director of the Institute for Applied Cancer Science, which merges the best attributes of academia and industry to enable science-driven drug discovery. 

 

Dr. Chin is a leader in translational genomic medicine, and her research program spans the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. Chin holds multiple leadership roles in The Cancer Genome Atlas, a comprehensive effort by the NIH to accelerate our understanding of the molecular basis of cancer through the use of genomics. She is a member of the Scientific Steering Committee of the International Cancer Genome Consortium.  Dr. Chin was elected a member of the Institute of Medicine in 2012.

 

A major focus of Dr. Chin’s current efforts is to bring to bear on the cancer crisis not only the transformative potential of genomics, but also of technologies and innovative strategies.  In particular, Dr. Chin has launched the N-of-ALLTM Initiative in the Department of Genomic Medicine with the goal of enhancing the effectiveness of cancer care and research through innovative solutions enabled by the big data revolution, advances in genomic and health IT technologies, and by a new culture of collaboration and cooperation between the research and clinical care enterprises in academia, as well as between academia and industry. An N-of-ALLTM pilot project in Leukemia has created an Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) platform that integrates genomic research in context of clinical standard of care and developed the first MD Anderson’s Oncology Expert AdvisorTM powered by IBM-Watson designed to facilitate democratization of oncology expertise.